Kolon Life Science to start clinical trials to extend Invossa’s target patient group - (The Korea Herald via NewsPoints Desk)

  • The Korea Herald reported that Kolon Life Science received permission from South Korea's Ministry of Food and Drug Safety to begin Phase III trials on Invossa, which is already approved to treat mid-grade osteoarthritis of the knee, for use in more severe forms of the disease.

  • Kolon Life Science said the new set of clinical trials, which will involve 146 patients in Korea, will start in January 2018 and continue for two years.

  • The injectable therapy was developed by Kolon Group's US-based subsidiary TissueGene, which seeks to amass evidence of Invossa's regenerative properties during Phase III trials slated to take place in the US next month.

  • The company is aiming to commercialize the drug in the US by 2023, according to the news source.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.